Eluminex announced today it acquired rights for a novel oral therapy to treat LCA or RP caused mutations of the RPE65 or LRAT gene.

Researchers developed and phenotyped a pigmented knockout rat model for lecithin retinol acyltransferase (LRAT) using CRISPR/Cas9.

Sawar Zahid MS, MD, Kari Branham MS, CGC, Dana Schlegel MS, MPH, CGC, Mark E. Pennesi MD, PhD, Michel Michaelides MB, MD, John...

Phenotypic similarities to the retinal dysfunction assoc. with RPE65 mutations, suggest that LRAT deficiency may respond to novel therapies.